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Major depression is a highly prevalent mood disorder, affecting about 350 million people,
and around 30% of the patients are resistant to currently available antidepressant
medications. Recent evidence from a randomized controlled trial (RCT) supports
the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant
depression. The aim of this study was to explore the effect of ayahuasca on
plasma cortisol and awakening salivary cortisol response, in the same group of
treatment-resistant patients (MD) and in healthy volunteers (C). Subjects received a single
dose of ayahuasca or placebo (dosing session), and both plasma and awakening salivary
cortisol response were measured at baseline (before dosing session) and 48 h after the
dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol
response and hypocortisolemia in patients, with respect to healthy controls. Salivary
cortisol was also measured during dosing session, and we observed higher increases for
both C andMD that ingested ayahuasca than placebo. After 48 h from the dosing session
with ayahuasca, patients’ awakening salivary cortisol response is similar to the ones
detected in controls. No significant changes in plasma cortisol levels were observed 48 h
after the sessions. Therefore, these findings point to new evidence on the modulation of
salivary cortisol levels as a result of an ayahuasca session, both in healthy and depressive
volunteers. Considering that cortisol acts in regulation of distinct physiological pathways,
emotional and cognitive processes, it is assumed to be critically involved to the etiology
of depression and its regulation seems to be important for the treatment and remission
of major depression, ayahuasca use as antidepressant should be further investigated.
Moreover, this study highlights the importance of psychedelics in the treatment of human
mental disorders.
Keywords: ayahuasca, awakening salivary cortisol, plasma cortisol, treatment-resistant depression,
hypocortisolemia
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INTRODUCTION
Major depression is a highly prevalent mood disorder, affecting
about 350 million people worldwide (1). It is more prevalent in
women than men and has a huge impact on general health of the
patients (1, 2).
Major depressive disorder has been closely associated with
deregulations of the hypothalamic-pituitary-adrenal (HPA) axis,
both at rest and in response to stress (3–5). Some studies report
changes in cortisol response that occur soon after awakening (6).
Most often reported, cortisol awakening response is increased
in patients with major depression, suggesting hyperactivity of
the HPA axis (7). However, there is increasing evidence of
hypocortisolism in patients with depression, which has been
interpreted as an indication of HPA axis fatigueness in response
to recurrent depressive episodes (8, 9). Such discrepancies can
be attributed to a number of factors including subtypes of
depression, depression severity, sex, duration of illness and
socioeconomic status (10–13).
Cortisol assessments have also served as an important
biomarker of treatment response. For instance, patients with
depression who responded to an 8-week treatment with
fluoxetine, a selective serotonin reuptake inhibitor, presented
decreased levels of cortisol (14).
Most often, patients are treated with antidepressant
medications that at present take about 2 weeks for the
beginning of their therapeutic effects (15–18). Recently,
however, psychedelics have been emerging as a promising
fast-acting antidepressant (19–23). A recent open label trial in
treatment-resistant depression observed a reduction of up to
87% in depression severity, already at 24 h after a single dosing
session with ayahuasca (23, 24). Ayahuasca was originally used
for medicinal purposes by indigenous populations from Brazil,
Ecuador, Peru, and Colombia, and later its ritualistic use became
more popular by its presence in ceremonies of different syncretic
churches in Brazil, which is currently spreading to other parts of
the world (25).
Ayahuasca is a decoction of two plants: Psychotria viridis
and Banisteriopses caapi (26). P. viridis contains the psychedelic
tryptamine N,N-dimethyltryptamine (N,N-DMT), whose action
is mediated by serotonin (5-HT2A) and sigma-1 receptors (27–
30). B. caapi contains β-carbolines (harmaline, harmine and
tetrahydroharmine), which work as indirect monoaminergic
agonist due to the inhibition of monoamine oxidase isoenzyme
(MAO) (31, 32). Regular ayahuasca users in religious contexts
have shown low level of psychopathologies (33–35), low scores
on the state scales related to panic and hopelessness (36), as
well as good performances in cognitive neuropsychological tests
(37, 38). Moreover, this brew does not exhibit dose tolerance, i.e.,
the decrease of the effect of a drug or medication by excessive or
frequent exposure of the patient to its active principle, and is not
addictive (39–41).
Considering that the main neurobiological actions of
ayahuasca are strongly related to key physiological systems
altered in major depression, i.e., was observed that ayahuasca
increased cortisol levels 2 h after its ingestion in healthy
subjects (42) and taking into account the low incidence of
mental disorders in regular ayahuasca users in religious context
and previous results from open label trial (23), we recently
conducted a randomized controlled trial (RCT) with ayahuasca
in patients with treatment-resistant depression. Our results
suggest significant and rapid reduction in depressive symptom
after a single ayahuasca session, when compared to placebo (43).
Herein, we explored the effects of ayahuasca on the awakening
salivary cortisol response and plasma cortisol, in patients with
treatment-resistant depression and in healthy individuals.
Our hypotheses are that patients and controls will show
different levels of plasma cortisol and awakening salivary cortisol
response, at baseline. Furthermore, we expect that the cortisol
levels in the group of patients will be correlated with the severity
and/or duration of disease. Moreover, we expect that ayahuasca,
but not placebo, will increase cortisol levels acutely, after the
dosing session and after 48 h of its ingestion, in patients and
controls. Changes in cortisol levels will be correlated with the
observed improvement in the symptoms of depression.
METHODS
This is a randomized double-blinded placebo-controlled trial
using a parallel arm design. Patients were referred from
psychiatric units of the Onofre Lopes University Hospital
(HUOL), in Natal/RN, Brazil, and through media and internet
advertisements. All procedures took place at the HUOL. The
authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national
and institutional committees on human experimentation and
with the Helsinki Declaration of 1975, as revised in 2008. The
study was approved by the Research Ethics Committee of the
University Hospital (# 579.479), and all subjects provided written
informed consent prior to participation. This study is registered
at http://clinicaltrials.gov (NCT02914769).
Volunteers
Seventy-one volunteers participated in the study: 43 healthy
controls (C) (19 men and 24 women) without history or
diagnosis of major illness or psychiatric disorders, and 28
patients with treatment resistant depression (MD), (7 men and
21 women), defined as those patients with inadequate responses
to at least two antidepressants from different classes (44).
Patients were screened for exclusion due to previous experience
with ayahuasca, current clinical medical disease, pregnancy,
current or previous history of neurological disorders, history
of schizophrenia, or bipolar affective disorder, history of mania
or hypomania, use of substances of abuse, and suicidal risk.
Selected patients were in a current moderate to severe depressive
episode at screening by the Hamilton Depression Rating Scale
(HAM-D≥17). All patients were not using any antidepressant
medication during the trial, they were in pharmacological wash-
out phase of approximately 2 weeks, however they all were under
regular use of benzodiazepines.
Volunteers from both groups (healthy and patients) were
randomly assigned (1:1) to receive ayahuasca or placebo using
10-gauge blocks. Half of the patients and half of the controls
received ayahuasca while the other half received placebo. All
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investigators and patients were blinded to the intervention
assignment. The Montgomery-Åsberg Depression Rating Scale
(MADRS) monitored depressive symptoms at admission of
patient to the psychiatry division of HUOL (D-1), and 2 days after
the dosing session (D2).
Ayahuasca and Placebo
The substance used as placebo was not psychoactive, but
induced a light gastrointestinal discomfort, and simulated some
organoleptic properties of ayahuasca. It is a brown liquid with
a bitter and sour taste, containing water, yeast, citric acid, zinc
sulfate, and a caramel dye.
A single batch of ayahuasca was used throughout the study.
It was prepared and supplied free of charge by a branch of the
Barquinha church, based in the city of Ji-Paraná, Brazil. The
alkaloid concentrations in the ayahuasca batch were analyzed
by mass spectroscopy twice during the trial. On average, the
ayahuasca contained (mean ± SD): 0.36 ± 0.01 mg/mL of N,N-
DMT, 1.86 ± 0.11 mg/mL of harmine, 0.24 ± 0.03 mg/mL of
harmaline and 1.20± 0.05 mg/mL of tetrahydroharmine (THH).
Salivary Cortisol
Saliva was collected using a specific cotton stick called Salivette
(Sarstedt, Germany). Volunteers were instructed to place the
cotton in their mouth without touching it and masticating it for
a period of about 1–2min. Before and during collection, subjects
remained at rest and no liquid or food were allowed.
Saliva samples were stored at −80◦C in the Laboratory of
Hormonal Measures of Federal University of Rio Grande do
Norte (UFRN) and the salivary cortisol was measured using the
ELISA DGR – SLV 4635 kit (DGR International, Inc, Germany).
Plasma Cortisol
Blood samples were collected for total plasma cortisol (PC)
assessment. All volunteers were at fast and at complete rest for
45min prior to blood sampling. Samples were stored at −80◦C
in the Laboratory of Hormonal Measures (UFRN). Total plasma
cortisol was measured by ELISA using the DGR-SLV 1887 kit
(DGR International, Inc, Germany).
Experimental Procedure
Figure 1 shows the experimental design of the study. After
screening phase, volunteers were admitted to the psychiatry
division of HUOL (admitted I) one night before dosing session
(D-1), when the MADRS scale of depression was applied for
patients. The volunteers slept in the hospital. At 6:00 a.m. the
next day (D0) saliva samples were collected for measuring
awakening salivary cortisol and at 7:00 a.m. the blood samples
were collected for PC assessment. Awakening salivary cortisol
response assessments consisted of 3 saliva samples collected at
(i) awakening (±5min), (ii)+30min, and (iii)+45min.
Dosing session started around 10:00 a.m. (D0). Volunteers
received a single dose of 1 ml/kg of ayahuasca (AYA) adjusted
to contain 0.36 mg/kg of N,N-DMT, or 1 ml/kg of placebo
(PLA). During the entire session subjects were asked to remain
quiet with their eyes closed while concentrating on their body,
thoughts and emotions. They could listen to a pre-defined music
playlist, if they wish. Volunteers were supported by at least
two researchers offering assistance when needed. Acute salivary
cortisol changes (%) were assessed during dosing session at two
instants: (i) immediately before dosing, and (ii)+1 h 40min after
the ingestion of placebo or ayahuasca.
On the following day (D1), volunteers slept again in the
hospital (admitted II). At 6:00 a.m. the next day (D2), 48 h
after dosing session, saliva samples were collected for measuring
awakening salivary cortisol, at 7:00 a.m. the blood samples were
collected for PC assessment and MADRS scale of depression was
applied for patients.
Statistical Analysis
Statistical analysis was conducted in Statistic 12.5 and the level of
significance was set at p < 0.05 for all tests. Graphics were built
in R 3.4.1 (RStudio).
The area under the curve (AUC) was calculated from the
3 points of salivary cortisol at waking time. Both salivary and
plasma cortisol levels were normalized by the logarithm to use
parametric tests.
A parametric test of Analysis of Covariance (ANCOVA) was
used to analyze differences between groups (healthy and patients)
at baseline, for both salivary (AUC of awakening salivary cortisol)
and plasma cortisol. Sex was inserted as co-variable.
At baseline, Spearman correlations were calculated between
the changes in clinical outcome scales (HAM-D and MADRS),
the duration of depression and both plasma cortisol and AUC of
awakening salivary cortisol.
General Linear Models (GLM) and Fisher post-hoc tests
were used to evaluate interaction between changes of AUC of
awakening salivary cortisol response at D0 and D2, considered as
dependent quantitative variable. Sex (men and women), groups
(healthy volunteers and patients) and treatment (AYA or PLA)
were considered as independent qualitative variables. General
Linear Models (GLM) and Fisher post-hoc tests were also used
for plasma cortisol levels. In this case, sex was not used as
independent variable, due to the small number of male patients
who received placebo (n= 2).
Acute salivary cortisol changes (%) during the dosing session
were evaluated 1 h 40 into the dosing session and assessed by
Mann-Whitney test.
Furthermore, Spearman correlations were calculated between
acute salivary cortisol changes (%), during the dosing session,
plasma cortisol (at D2), AUC of awakening salivary cortisol (at
D2) and with MADRS scores (at D2).
RESULTS
Socio-demographic characteristics of healthy controls (C), and
patients with major depression (MD) are summarized in Table 1.
All volunteers (n = 71; MD = 28, C = 43) are Brazilian, adults
[MD = 41.54 ± 11.55, C = 31.21 ± 9.87 years, t(69) = 4.03
p < 0.0001]. From January 2014 to June 2016, 218 patients
were screened for eligibility, and 35 met criteria for the trial.
On average, patients presented 11.03 ± 9.70 years of depressive
symptoms and met criteria for moderate-to-severe depression
(HAM-D= 21.83± 5.35). They were treated previously with 3.86
± 1.66 different types of antidepressants and two patients used
electroconvulsive therapy as treatment. The majority of patients
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FIGURE 1 | Experimental design. In baseline (color: light gray) patients with treatment resistant depression (MD: 7 men and 21 women) and healthy controls (C: 19
men and 24 women) were selected in the screening phase. MD were in a pharmacological wash-out phase (±2 weeks) and were screening by the Hamilton
Depression Rating Scale (HAM-D). In D-1 all volunteers slept at the hospital (admitted I) and Montgomery-Åsberg Depression Rating Scale (MADRS) scale of
depression was applied for DM. At D0, plasma, and saliva collection at awake were performed for cortisol dosage. Around 10:00 a.m. happened dosing session with
ayahuasca (AYA) or placebo (PLA) (color: gray). Acute salivary cortisol changes (%) were assessed during dosing session. At D1 all volunteers slept again at the
hospital (admitted II) and on D2 (48 h after dosing session) plasma and saliva collection at awake were performed and MADRS was applied (color: dark gray).
TABLE 1 | Socio-demographic characteristics of 71 volunteers who participated
in the study: 43 healthy controls (19 men and 24 women) without history or
diagnosis of major illness or psychiatric disorders, and 28 patients with
treatment-resistant depression (7 men and 21 women).
Controls Patients Statistical analysis
Participants, n 43 28
Age (years) 31.21 ± 9.87 41.54 ± 11.55 t(69) = 4.03 p < 0.0001
Gender (M/F) 19/24 7/21 X2(1) = 2.69 p =0.10
Unemployed (%) 5/43 (12) 15/28 (54) X2(1) = 14.74 p < 0.0001
Household income X2(3) = 14.03 p = 0.003
< 5 wages (%) 19/86 (71) 22/56 87
6–10 wages (%) 14/43(7) 2/28 (6.6)
11 or more wages (%) 10/43 (21) 4/28 (6.6)
Education X2(3) = 19.88 p = 0.0002
Up to 8 years, n (%) 3/43 (7) 11/28 (39)
9–11 years, n (%) 4/43 (9) 8/28 (29)
12–16 years, n (%) 18/43(42) 4/28 (14)
17 or more years, n (%) 18/43 (42) 5/28 (18)
presented comorbidity, such as personality disorder (76%) and
anxiety disorder (31%).
Patients showed significant lower socioeconomic status
backgrounds than healthy volunteers: large part of the MD group
was from low socioeconomic status, unemployed [MD = 54%,
C = 12%, X2(1) = 4.74, p < 0.0001], earning up to 5 minimum
wages [MD = 87%, C = 71%, X2(3) = 14.03, p = 0.003] and
with up to 8 years of formal education [MD = 39%, C = 7%,
X2(3)= 19.88, p= 0.0002].
Baseline Assessments
Figure 2 shows the cortisol levels at baseline (D0). Figure 2A
shows the AUC of awakening salivary cortisol response for both
groups (C and MD) at baseline. AUC level at baseline was
lower for patients (MD; n = 20, µ = 49.4 ± 8.3 cm2) than
healthy controls (C; n = 41, µ = 62.5 ± 6.3 cm2), and these
differences were independent of sex (ANCOVA main effects:
Group∗: F = 9.75 df = 1 p = 0.002, Sex∗: F = 0.42 df = 1
p = 0.51). Figure 2B shows the results for plasma cortisol
(mcg/dL). The same profile is observed in plasma cortisol at
baseline, which was lower in patients (MD; n = 28, µ = 15.12
± 1.73 mcg/dL) than in healthy controls (C; n= 43, µ= 19.52±
1.37 mcg/dL). Again, these differences were independent of sex
(ANCOVAmain effects: Group∗: F = 4.71 df = 1 p= 0.03, Sex∗:
F = 0.89 df = 1 p= 0.34). Figure 2B also illustrates patients that
show relative (n=17 and 61%) and true hypocortisolemia (n = 6
and 22.22%), with total plasma cortisol levels below 15 and 10
mcg/dL, respectively.
At baseline a significant positive correlation was observed
between cortisol levels (plasma and AUC) in D0, for controls
(p < 0.05 rs = 0.54), but not for patients. No significant
correlations were found between cortisol levels (plasma and
salivary), depression severity (HAM-D and MADRS), and
duration of disease for patients (Supplementary Table 1 for
details).
Acute Effects of Ayahuasca (Dossing
Session)
Figure 3 shows the acute salivary cortisol changes (%) during
the dosing session of salivary cortisol observed 1 h 40 after
ayahuasca or placebo ingestion. Figure 3A shows that patients in
the ayahuasca group (n = 10) presented greater salivary cortisol
increases (median = 98.72; Q25% = 37.89; Q75% = 177.16)
compared to the placebo group (n = 12) (median = 23.26;
Q25% = −5.44; Q75% = 41.65) (Mann-Whitney test U = 27
p = 0.03). Figure 3B shows the same analyses for the control
group. Controls of the ayahuasca group (n = 21) showed
greater increases of salivary cortisol levels (median = 146.87;
Q25% = 53.32; Q75% = 211.84) compared to the placebo group
(n = 20) (median = 38.50; Q25% = 10.33; Q75% = 60.27)
(Mann-Whitney test U = 84 p = 0.01). Figure 3C compares
patients and controls that ingested ayahuasca, both showing
similar changes of salivary cortisol at 1 h 40min after ingestion
of ayahuasca (Mann-Whitney test U = 85 p = 0.66; patients
median = 98.72; Q25% = 37.89; Q75% = 177.16, controls
median= 146.87; Q25%= 53.32; Q75%= 211.84). Acute salivary
cortisol changes (%) observed during dosing session for patients
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FIGURE 2 | Mean and standard deviation of cortisol levels at baseline (D0).
(A) AUC of awakening salivary cortisol for the control group (C, closed triangle)
and patients (MD, closed circle). (B) Plasma cortisol (mcg/dL). Relative
hypocortisolemia (<15 mcg/dL) = dark gray symbols and true
hypocortisolemia (<10 mcg/dL) = light gray symbols). Each symbol (triangle or
circle) indicate individual value of cortisol. *p ≤ 0.05, statistically significant
difference between-groups. GLM test and post-hoc Fisher.
were not significantly correlated with MADRS scores at D2
(Supplementary Table 2 for details).
Post-treatment Assessments (D2)
No changes in AUC between D0 and D2, for within groups
and treatments were observed. (GLM: Group∗Treatment∗Days:
F = 4.57, p= 0.03, Supplementary Tables 3, 4 for details). At D2,
AUC of patients who ingested ayahuasca (µ = 59.4 ± 12.7 cm2)
is similar to values of controls group who ingested ayahuasca
(µ = 50.1 ± 8.2 cm2) (Fisher post-hoc: p = 0.45). On the other
hand, patients that ingested placebo continued presenting lower
AUC (µ = 41.2 ± 14.8 cm2) than controls that ingested placebo
(µ= 61.9± 8.9 cm2) (Fisher post-hoc: p= 0.03). Influence of sex
was not observed for AUC (supplementary Table 3 for details).
Figure 4 shows AUC of awakening salivary cortisol response
for both groups (C and MD) and treatments (ayahuasca and
FIGURE 3 | Median Q25 and Q75 of acute salivary cortisol changes (%) at 1 h
40min into the dosing session. (A) For patients with major depression (MD,
closed circle) after ayahuasca (AYA, blue color), or placebo (PLA, red color)
ingestion. (B) Control group (C, closed triangle) after ayahuasca or placebo
ingestion. (C) MD and C after ayahuasca ingestion. *p ≤ 0.05, statistically
significant difference between-groups. Mann-Whitney non-parametric test.
placebo) 48 h after dosing session (D2). Individual changes of
AUC between D0 and D2 were illustrated for each group and
treatment in Supplementary Figure 1.
For plasma cortisol no significant changes were
observed between D0 and D2, within both groups (MD
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FIGURE 4 | Mean and standard deviation of area under the curve (AUC) of
awakening salivary cortisol 48 h after dosing (D2) of control group (C, closed
triangle) and patients with major depression (MD, closed circle) who ingested
ayahuasca (blue color) or placebo (red color). *p <0.05, statistically significant
difference between-groups. GLM test and post-hoc Fisher.
and C) and treatment (ayahuasca or placebo) (GLM:
Group∗Treatment∗Days: F = 1.24, p = 0.27, Supplementary
Table 5 for details). Individual changes in PC between D0 and D2
are illustrated for each group and treatment in Supplementary
Figure 2.
No statically significant correlations were observed between
plasma cortisol and AUC of awakening salivary cortisol of D2
for patients nor controls, nor with MADRS scores in the patients
group. A detailed description of the Spearman correlation results
are presented in Supplementary Table 2.
DISCUSSION
In this study we found basal hypocortisolemia and blunted
awakening salivary cortisol response in patients with treatment-
resistant depression, compared to healthy controls. During
dosing, 1 h 40min after ingestion, we observed significant acute
increases in salivary cortisol in the ayahuasca groups (C and
MD), compared to placebo groups (C and MD). Moreover, 48 h
after the dosing session (D2) with ayahuasca, patients’ awakening
salivary cortisol response is similar to levels detected in healthy
controls. This was not observed in patients that ingested placebo,
which continued showing different AUC of awakening salivary
cortisol response compared to the control group. No significant
differences were found in D2 regarding plasma cortisol.
In our recent randomized placebo-controlled trial we
observed a significant antidepressant effect after a single dosing
session with ayahuasca, when compared to placebo. Depression
severity diminished significantly 1 day after dosing, and between-
group differences increased from D1 to D7 (43).
Our results partially corroborate our initial hypothesis. We
expected different levels of cortisol between patients and controls
at baseline and, in fact, cortisol levels (both plasma and salivary)
were reduced in the group of patients when compared to
healthy controls. We also estimated that the cortisol levels
will be correlated with the severity and/or duration of disease.
Unexpectedly, cortisol levels (plasma and salivary) observed in
the group of patients were not correlated with severity nor disease
duration. Nevertheless, at baseline, a positive correlation between
plasma and AUC of awakening salivary cortisol levels was found
for controls, but not for patients.
Cortisol is a steroid hormone that triggers stress response
in an adaptive way: it increases cardiovascular and respiratory
activity, mobilizes glucose to provide enough fuel to remove
the stressor and limit acute inflammation processes (45). Not
only the excess, but also the reduction of cortisol is believed to
be harmful. Major depression has been traditionally associated
with hypercortisolism, but an increasing number of studies have
found evidence of hypocortisolism in depression (8, 46, 47).
Chronic decreased cortisol levels induce non-specific symptoms
such as general malaise, weakness, low blood pressure, muscle
weakness, loss of appetite and weight, gastrointestinal complaints
and immunological dysfunction (48), some of which are very
common in major depression. Besides depression, low cortisol
levels have been found in some other conditions, such as
Addison’s disease (49), adrenal insufficiency (50, 51), and post-
traumatic stress disorders (52).
In the literature, more severe depression, marked by chronic
or recurrent disease episodes, is frequently accompanied by
hypocortisolemia (8, 46, 47). These patients often exhibit long-
term exposition to stressors, which in the early phase of the
disease may induce chronic upregulated activity of the HPA
axis and hypercortisolemia, followed by reducing cortisol to
very low pathological levels (53, 54). In addition, evidence
suggests that prolonged use of some antidepressants may also
lead to increased expression of cortisol receptors and increased
sensitivity of negative feedback, thus decreasing cortisol levels to
under homeostatic values (55). Our patients were all treatment-
resistant and used an average of 3.86 ± 1.66 different types of
antidepressants, which could in turns induced hypocortisolemia.
Low cortisol levels in depression have also been associated with
maladaptive coping style (56) and unfavorable socioeconomic
status (13, 57). Patients in this study had a particular profile:
they were all from low socioeconomic status background, low
educated and living in a low-income household, in a stressful
environment. Previous studies have reported similar results.
They found low levels of cortisol at awakening in patients with
depression from the same region, compared to healthy controls
(58), andwith patients fromCanada (58). Due to significant levels
of poverty and scarce government investments in this region, this
population usually is submitted to a long exposure of adverse
events in life, and early in life they cope with precarious physical
and physiological health, as well as with cumulative social and
economic disadvantageous conditions.
The etiology of hypocortisolism is explained by various
theories. One of them shows that a greater and decompensated
sensitivity in negative feedback of the HPA axis deregulates
cortisol secretion (54). Also, hypocortisolism is associate to
adrenal insufficiency, a failure to produce cortisol and a
decrease or increase in Adrenocorticotrophic hormone (ACTH)
concentrations that depend on the type of failure, whether
primary or secondary, respectively (48). New evidence also points
Frontiers in Psychiatry | www.frontiersin.org 6 May 2018 | Volume 9 | Article 185
Galvão et al. Ayahuasca Modulates Cortisol in Depression
to the participation of paracrine and autocrine messengers in
adrenal failure (59). While several theories try to explain the
etiology of hypocortisolism, it seems that the best approach to
elucidate this pathophysiological process involves the integration
of all these theories.
The regulation of cortisol is an important physiological aspect
on the way of achieving biological health, since cortisol is an
integrative hormone with large potential of body modulation,
particularly involved in the etiology of depression, engaging the
immune, and monoaminergic systems (53, 60, 61). Moreover,
optimal levels of cortisol are necessary to induce neurogenesis,
possibly due to its modulatory properties over brain-derived
neurotrophic factor (BDNF) (62, 63). This relation seems to be
an important factor in the etiology of depression, considering
that the effectiveness of traditional antidepressants seems to be
mediated by neuronal plasticity and neurogenesis (64).
The reference values for the diagnosis of corticosteroid
insufficiency vary. Some studies define hypocortisolemia when
cortisol levels are below 15 mcg/dL, others define it under
10 mcg/dL (65–67). Studies that evaluated the utility of basal
morning serum cortisol measurements in the diagnosis of
adrenal insufficiency showed that a threshold of 10 mcg/dL leads
to 77% of specificity, and 62% sensitivity, defined by a subnormal
serum cortisol response to insulin-induced hypoglycemia (68,
69). Therefore, in this study we considered 10 mcg/dL as cutoff
reference value for true hypocortisolemia. We observed that 61%
of our patients showed relative hypocortisolemia (<15 mcg/dL),
and 22% true hypocortisolemia (<10 mcg/dL). On the other
hand, awakening salivary cortisol response has been less used
than plasma cortisol to monitor adrenal insufficiency, as it has
not been fully validated as a diagnostic test.
Plasma cortisol levels were positively correlated with saliva
cortisol levels at baseline for controls, but not for patients, in
line with previous studies that observed a correlation between
total plasma and salivary cortisol in healthy subjects (70). The
absence of correlation in the groups of patients could be due to a
malfunction of the HPA axis (70) or by changes in concentration
of CBG (Cortisol Binding Globulin), its transporter protein in the
plasma (71).
Moreover, we also supposed that ayahuasca, but not placebo,
could acutely increase cortisol levels, after the dosing session,
in patients and controls. The large increase in cortisol levels by
ayahuasca found 1 h 40 after intake, for health and depressive
volunteers, corroborated our hypothesis. Previous studies in
healthy subjects have also reported increased cortisol levels
during the acute effects of ayahuasca (72–74), N,N-DMT (75),
psilocybin (76, 77), and Lysergic Acid Diethylamide (LSD)
(78). One should bear in mind that our patients presented,
in general, hypocortisolemia, and blunted awakening salivary
cortisol response. It is reasonable to consider that subjects
who took ayahuasca, which immediately increased cortisol
levels, probably were acutely benefited by the ingestion of the
ayahuasca, thereby leading to a direction of achieving hormonal
homeostasis.
The modulation of the HPA axis by antidepressants
depends on the type of antidepressant used and treatment
duration, acute or chronic. Noradrenaline or serotonin (5HT)
reuptake-inhibiting antidepressants, such as reboxetine and
citalopram, acutely stimulate cortisol secretion in healthy
volunteers, probably due the elevation in 5HT levels (79, 80).
On the other hand, some antidepressants, as mirtazapine,
acutely inhibits cortisol release, probably due to its selective
antagonism at 5-HT2 receptors (79). It is interesting to notice
that the long-term effects of antidepressants are frequently
opposite to the acute ones. In the long way, reboxetine up-
regulates cortisol receptors function, repairs the disturbed
feedback control and normalizes HPA axis. Mirtazapine, within
1 week, markedly reduces HPA axis activity in depressed patients
(79, 80). If the patient is resistant to treatments, and uses
antidepressants by years, the long-term effects could be disturbed
and followed by an unfavorable physiological response, and as
cited above, the chronic use of some antidepressant could induce
hypocortisolemia.
Here, the acute increases of cortisol levels by the ayahuasca
can be due the rise in serotonin induced by the N,N-DMT,
and β-carbolinic alkaloids (31), likewise, other studies support
the modulation by serotonin on the secretion of Corticotrophin
Releasing Hormone (CRH) and ACTH both at the hypothalamic
and pituitary glands (81).
After 48 h of the dosing session (D2), no changes in cortisol
levels were observed comparing to baseline levels, within each
group, and between treatments, neither in AUC of awakening
salivary cortisol response nor in the plasma. These results were
different than the claim of our initial hypothesis: previously, we
expected an increase in cortisol levels (plasma and salivary) in
D2. Individual analysis of AUC and PC at D0 and D2 showed
a large individual variability. Some studies also faced with this
large individual variability at baseline levels and response of
cortisol (82). However, after 48 h from the dosing session, the
AUC of awakening salivary cortisol response of patients that
ingested ayahuasca, and not placebo, is similar to control that
ingested ayahuasca. This similarity of AUC between controls and
patients that were treated with ayahuasca points to a beneficial
physiological modulation by ayahuasca on awakening salivary
cortisol response. This finding probably corroborates with the
improvement of several physiological systems, emotional and
cognitive aspects that are regulated by cortisol (83, 84). Despite
cortisol levels showed large inter and intra-individual variability,
and as the area under the curve of awakening salivary cortisol
consisted of three saliva samples collected in the early morning
hours, some studies have been considering the awakening
salivary cortisol response as more reliable biomarker than
plasma. Awakening salivary cortisol response was demonstrated
to be sensible to treatment by antidepressants (47, 85–88),
probably because this index is less modulated by circadian clock
and daily stressors than plasma cortisol levels (89).
Some studies with animal models of depression, rodents
and non-human primates, observed positive antidepressant
effects with the use of ayahuasca or its specific components
(90–92). Using the recently validated translational animal
model of depression (93), young marmosets (Callithrix
jacchus) that showed hypocortisolemia, were treated with
nortriptyline during 7 days, a tricyclic antidepressant, or with
a single dose of ayahuasca. It was observed that ayahuasca
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increased fecal cortisol levels until 48 h after it ingestion,
and presented more notable antidepressant effects than
nortriptyline, since it reverted depressive-like behaviors and
regulated cortisol levels faster and longer, when compared with
nortriptyline (93).
Although there is great evidence that normalization of HPA
axis function is essential for the successful treatment of depressive
patients (89, 94, 95) differently of our hypothesis, herein changes
in cortisol levels induced by ayahuasca were not correlated with
improvement in depressive symptoms observed from D1 to D7
after it intake. We speculate that this fact is probably due to
the high heterogeneity of patients and relative small sample of
volunteers per group in this study.
The present study supports the involvement of the HPA
axis in the physiopathology of depression and the modulation
of salivary cortisol by a single session with ayahuasca, both
in depressive patients and healthy volunteers. The cortisol acts
in regulation of distinct physiological, cognitive and emotional
pathways, and previous studies suggested that regulation of its
levels to standard values is considered as an important part of
depression treatment. Thus, we argue that ayahuasca should be
further investigated as treatment of depression. Taking these
findings in account, this work contributes significantly to support
the return of clinical studies with natural psychedelics applied to
mental disorders.
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